Clinical trial disclosure

A study comparing a new bowel cleansing agent, NER1006, with another bowel cleansing agent, Sodium Picosulfate and Magnesium Salt (SP+MS), using day-before dosing. Click here to read the cover page.

A study comparing a new bowel cleansing agent, NER1006, with a standard agent, MOVIPREP®. Click here to read the cover page.

A study comparing a new bowel cleansing agent, NER1006, with a standard agent, Trisulfate Solution. Click here to read the cover page.

Pilot study to assess the diagnostic value of the cholyl lysyl fluorescein (NRL972) assay in cystic fibrosis patients with known advanced liver disease.

A randomised, open, controlled crossover study in male and female healthy volunteers to describe the plasma pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) during and after a constant rate 2 hour iv-infusion of 5 and 15 mg NRL972 per hour.

An open, randomised study to compare the reproducibility of CTP rating and NRL972 pharmacokinetics in patient volunteers with hepatic cirrhosis

A single-centre, open, controlled, randomised cross-over study in healthy male and female volunteers to evaluate the pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) in the presence of medication-induced changes in cytochrome P450 or biliary transporter proteins.

A multi-centre, multi-national open study in patients with hepatic cirrhosis to characterise the association between the pharmacokinetics of NRL972 and disease severity.

A multi-centre, open, short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting.

A single-centre, open, uncontrolled study in healthy male and female volunteers to describe the plasma pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) during and after a constant rate i.v. infusion.

A single-centre, open, controlled, randomised cross-over study in healthy male and female volunteers to investigate the effects of the injection volume and injection time on the pharmacokinetics of cholyl-lysyl-fluorescein (NRL972).

A randomised, placebo-controlled, double-blind, double-dummy, four-way crossover, single-centre study to investigate the effects of 2 mg and 10 mg intravenously administered NRL972 on the QTC interval in healthy volunteers.

A double-blind, randomised, single dose, crossover study to investigate the plasma clearance of two different doses of CLF (NRL972) in 24 volunteers with stable non-cholestatic liver cirrhosis.

An open-label, randomised 2 part scintigraphic study in 2 parallel groups of healthy male subjects. Each group attended the clinical unit for a baseline period (administered water) and a test period (administered KLEAN-PREP^® or MOVIPREP^®).